The Concordance between Nonclinical and Phase I Clinical Cardiovascular Assessment from a Cross-Company Data Sharing Initiative

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

(2014) David Cook et al.   NATURE REVIEWS DRUG DISCOVERY

Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium

(2013) Philip Sager et al.   AMERICAN HEART JOURNAL

Revolution dawning in cardiotoxicity testing

(2013) Kelly Rae Chi   NATURE REVIEWS DRUG DISCOVERY

Translational pharmacokinetic–pharmacodynamic modeling of QTc effects in dog and human

(2013) Joanna Parkinson et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

The ability of animal studies to detect serious post marketing adverse events is limited

(2012) Peter J.K. van Meer et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

(2011) HG Laverty et al.   BRITISH JOURNAL OF PHARMACOLOGY

Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the Safety Pharmacology Society

(2011) D.J. Leishman et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development

(2010) F. Peter Guengerich   Drug Metabolism and Pharmacokinetics

Cardiovascular safety assessments in the conscious telemetered dog: Utilisation of super-intervals to enhance statistical power

(2010) A. Sivarajah et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Lessons from 60 years of pharmaceutical innovation

(2009) Bernard Munos   NATURE REVIEWS DRUG DISCOVERY

A framework to assess the translation of safety pharmacology data to humans

(2009) Jean-Pierre Valentin et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS